John Julian Harvey
Research Subjects
John Julian Harvey has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Raman Uberoi
Department of Radiology; John Radcliffe NHS Trust Hospital; Oxford UK
3 shared publicationsArul Ganeshan
Department of Interventional Radiology, Birmingham Heartlands Hospital, The Heart of England NHS Trust , Birmingham, UK
2 shared publicationsShiwei Huang
St George Hosp, Dept Radiol, Kogarah, NSW, Australia
2 shared publicationsA. Ganeshan
Department of Radiology, Heart of England NHS Trust, Heartlands hospital, Bordesley Green East, Birmingham, West Midlands, UK
1 shared publicationA.T.H. West
1 shared publicationAndrew H. Holden
University of Auckland Medical School, Auckland, New Zealand
1 shared publication
Latest Publications
- 21 September 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (1) , 161-162
Navigational Bronchoscopy Versus Transthoracic Needle Biopsy for Solid Peripheral Lung Nodules: Complementary Rather than Competitors?
- 21 September 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (1) , 161-162
Navigational Bronchoscopy Versus Transthoracic Needle Biopsy for Solid Peripheral Lung Nodules: Complementary Rather than Competitors?
- Open Access
- 15 February 2024
- Published by Wiley in Medical Journal of Australia
- Vol. 220 (5) , 238-240
Catheter‐related superior vena cava syndrome: an increasing problem
- 15 February 2024
- Published by Wiley in Medical Journal of Australia
- Vol. 220 (5) , 238-240
Open AccessCatheter‐related superior vena cava syndrome: an increasing problem
- Open Access
- 30 November 2022
- Published by Wiley in Medical Journal of Australia
- Vol. 218 (1) , 18-21
Diagnostic and therapeutic abdominal paracentesis
- 30 November 2022
- Published by Wiley in Medical Journal of Australia
- Vol. 218 (1) , 18-21
Open AccessDiagnostic and therapeutic abdominal paracentesis
- 8 August 2022
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2022 (8) , CD013083
Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism
Background Acute pulmonary embolism (APE) is a major cause of acute morbidity and mortality. APE results in long‐term morbidity in up to 50% of survivors, known as post‐pulmonary embolism (post‐PE) syndrome. APE can be classified according to the short‐term (30‐day) risk of mortality, based on a variety of clinical, imaging and laboratory findings. Most mortality and morbidity is concentrated in high‐risk (massive) and intermediate‐risk (submassive) APE. The first‐line treatment for APE is systemic anticoagulation. High‐risk (massive) APE accounts for less than 10% of APE cases and is a life‐threatening medical emergency, requiring immediate reperfusion treatment to prevent death. Systemic thrombolysis is the recommended treatment for high‐risk (massive) APE. However, only a minority of the people affected receive systemic thrombolysis, due to comorbidities or the 10% risk of major haemorrhagic side effects. Of those who do receive systemic thrombolysis, 8% do not respond in a timely manner. Surgical pulmonary embolectomy is an alternative reperfusion treatment, but is not widely available. Intermediate‐risk (submassive) APE represents 45% to 65% of APE cases, with a short‐term mortality rate of around 3%. Systemic thrombolysis is not recommended for this group, as major haemorrhagic complications outweigh the benefit. However, the people at higher risk within this group have a short‐term mortality of around 12%, suggesting that anticoagulation alone is not an adequate treatment. Identification and more aggressive treatment of people at intermediate to high risk, who have a more favourable risk profile for reperfusion treatments, could reduce short‐term mortality and potentially reduce post‐PE syndrome. Catheter‐directed treatments (catheter‐directed thrombolysis and catheter embolectomy) are minimally invasive reperfusion treatments for high‐ and intermediate‐risk APE. Catheter‐directed treatments can be used either as the primary treatment or as salvage treatment after failure of systemic thrombolysis. Catheter‐directed thrombolysis administers 10% to 20% of the systemic thrombolysis dose directly into the thrombus in the lungs, potentially reducing the risks of haemorrhagic side effects. Catheter embolectomy mechanically removes the thrombus without the need for thrombolysis, and may be useful for people with contraindications for thrombolysis. Currently, the benefits of catheter‐based APE treatments compared with existing medical and surgical treatment are unclear despite increasing adoption of catheter treatments by PE response teams. This review examines the evidence for the use of catheter‐directed treatments in high‐ and intermediate‐risk APE. This evidence could help guide the optimal treatment strategy for people affected by this common and life‐threatening condition. Objectives To assess the effects of catheter‐directed therapies versus alternative treatments for high‐risk (massive) and intermediate‐risk (submassive) APE. Search methods We used standard, extensive Cochrane search methods. The latest search was 15 March 2022. Selection criteria We included randomised controlled trials (RCTs) of catheter‐directed therapies for the treatment of high‐risk (massive) and intermediate‐risk (submassive) APE. We excluded catheter‐directed treatments for non‐PE. We applied no restrictions on participant age or on the date, language or publication status of RCTs. Data collection and analysis We used standard Cochrane methods. The main outcomes were all‐cause mortality, treatment‐associated major and minor haemorrhage rates based on two established clinical definitions, recurrent APE requiring retreatment or change to a different APE treatment, length of hospital stay, and quality of life. We used GRADE to assess certainty of evidence for each outcome. Main results We identified one RCT (59 participants) of (ultrasound‐augmented) catheter‐directed thrombolysis for intermediate‐risk (submassive) APE. We found no trials of any catheter‐directed treatments (thrombectomy or thrombolysis) in people with high‐risk (massive) APE or of catheter‐based embolectomy in people with intermediate‐risk (submassive) APE. The included trial compared ultrasound‐augmented catheter‐directed thrombolysis with alteplase and systemic heparinisation versus systemic heparinisation alone. In the treatment group, each participant received an infusion of alteplase 10 mg or 20 mg over 15 hours. We identified a high risk of selection and performance bias, low risk of detection and reporting bias, and unclear risk of attrition and other bias. Certainty of evidence was very low because of risk of bias and imprecision. By 90 days, there was no clear difference in all‐cause mortality between the treatment group and control group. A single death occurred in the control group at 20 days after randomisation, but it was unrelated to the treatment or to APE (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.01 to 7.96; 59 participants). By 90 days, there were no episodes of treatment‐associated major haemorrhage in either the treatment or control group. There was no clear difference in treatment‐associated minor haemorrhage between the treatment and control group by 90 days (OR 3.11, 95% CI 0.30 to 31.79; 59 participants). By 90 days, there were no episodes of recurrent APE requiring retreatment or change to a different APE treatment in the treatment or control group. There was no clear difference in the length of mean total hospital stay between the treatment and control groups. Mean stay was 8.9 (standard deviation (SD) 3.4) days in the treatment group versus 8.6 (SD 3.9) days in the control group (mean difference 0.30, 95% CI...
- 8 August 2022
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2022 (8) , CD013083
Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism
Background Acute pulmonary embolism (APE) is a major cause of acute morbidity and mortality. APE results in long‐term morbidity in up to 50% of survivors, known as post‐pulmonary embolism (post‐PE) syndrome. APE can be classified according to the short‐term (30‐day) risk of mortality, based on a variety of clinical, imaging and laboratory findings. Most mortality and morbidity is concentrated in high‐risk (massive) and intermediate‐risk (submassive) APE. The first‐line treatment for APE is systemic anticoagulation. High‐risk (massive) APE accounts for less than 10% of APE cases and is a life‐threatening medical emergency, requiring immediate reperfusion treatment to prevent death. Systemic thrombolysis is the recommended treatment for high‐risk (massive) APE. However, only a minority of the people affected receive systemic thrombolysis, due to comorbidities or the 10% risk of major haemorrhagic side effects. Of those who do receive systemic thrombolysis, 8% do not respond in a timely manner. Surgical pulmonary embolectomy is an alternative reperfusion treatment, but is not widely available. Intermediate‐risk (submassive) APE represents 45% to 65% of APE cases, with a short‐term mortality rate of around 3%. Systemic thrombolysis is not recommended for this group, as major haemorrhagic complications outweigh the benefit. However, the people at higher risk within this group have a short‐term mortality of around 12%, suggesting that anticoagulation alone is not an adequate treatment. Identification and more aggressive treatment of people at intermediate to high risk, who have a more favourable risk profile for reperfusion treatments, could reduce short‐term mortality and potentially reduce post‐PE syndrome. Catheter‐directed treatments (catheter‐directed thrombolysis and catheter embolectomy) are minimally invasive reperfusion treatments for high‐ and intermediate‐risk APE. Catheter‐directed treatments can be used either as the primary treatment or as salvage treatment after failure of systemic thrombolysis. Catheter‐directed thrombolysis administers 10% to 20% of the systemic thrombolysis dose directly into the thrombus in the lungs, potentially reducing the risks of haemorrhagic side effects. Catheter embolectomy mechanically removes the thrombus without the need for thrombolysis, and may be useful for people with contraindications for thrombolysis. Currently, the benefits of catheter‐based APE treatments compared with existing medical and surgical treatment are unclear despite increasing adoption of catheter treatments by PE response teams. This review examines the evidence for the use of catheter‐directed treatments in high‐ and intermediate‐risk APE. This evidence could help guide the optimal treatment strategy for people affected by this common and life‐threatening condition. Objectives To assess the effects of catheter‐directed therapies versus alternative treatments for high‐risk (massive) and intermediate‐risk (submassive) APE. Search methods We used standard, extensive Cochrane search methods. The latest search was 15 March 2022. Selection criteria We included randomised controlled trials (RCTs) of catheter‐directed therapies for the treatment of high‐risk (massive) and intermediate‐risk (submassive) APE. We excluded catheter‐directed treatments for non‐PE. We applied no restrictions on participant age or on the date, language or publication status of RCTs. Data collection and analysis We used standard Cochrane methods. The main outcomes were all‐cause mortality, treatment‐associated major and minor haemorrhage rates based on two established clinical definitions, recurrent APE requiring retreatment or change to a different APE treatment, length of hospital stay, and quality of life. We used GRADE to assess certainty of evidence for each outcome. Main results We identified one RCT (59 participants) of (ultrasound‐augmented) catheter‐directed thrombolysis for intermediate‐risk (submassive) APE. We found no trials of any catheter‐directed treatments (thrombectomy or thrombolysis) in people with high‐risk (massive) APE or of catheter‐based embolectomy in people with intermediate‐risk (submassive) APE. The included trial compared ultrasound‐augmented catheter‐directed thrombolysis with alteplase and systemic heparinisation versus systemic heparinisation alone. In the treatment group, each participant received an infusion of alteplase 10 mg or 20 mg over 15 hours. We identified a high risk of selection and performance bias, low risk of detection and reporting bias, and unclear risk of attrition and other bias. Certainty of evidence was very low because of risk of bias and imprecision. By 90 days, there was no clear difference in all‐cause mortality between the treatment group and control group. A single death occurred in the control group at 20 days after randomisation, but it was unrelated to the treatment or to APE (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.01 to 7.96; 59 participants). By 90 days, there were no episodes of treatment‐associated major haemorrhage in either the treatment or control group. There was no clear difference in treatment‐associated minor haemorrhage between the treatment and control group by 90 days (OR 3.11, 95% CI 0.30 to 31.79; 59 participants). By 90 days, there were no episodes of recurrent APE requiring retreatment or change to a different APE treatment in the treatment or control group. There was no clear difference in the length of mean total hospital stay between the treatment and control groups. Mean stay was 8.9 (standard deviation (SD) 3.4) days in the treatment group versus 8.6 (SD 3.9) days in the control group (mean difference 0.30, 95% CI...
- 1 May 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (6) , e8-e9
Not What You Think?
- 1 January 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (1) , e13-e14
A Remote Cause of Epigastric Pain
- 1 January 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (1) , e13-e14
A Remote Cause of Epigastric Pain
- 31 July 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (7)
Catheter-directed therapies for the treatment of massive and submassive acute pulmonary embolism
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of catheter-directed therapies versus alternative treatments for massive and submassive acute pulmonary embolism.
- 31 July 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (7)
Catheter-directed therapies for the treatment of massive and submassive acute pulmonary embolism
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of catheter-directed therapies versus alternative treatments for massive and submassive acute pulmonary embolism.
- Open Access
- 1 May 2016
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 2 (2) , 20150127
Tension pneumocephalus: the neurosurgical emergency equivalent of tension pneumothorax
Tension pneumocephalus (TP) is the intra-cranial equivalent of tension pneumothorax. It is rare a life-threatening neurosurgical emergency, which has been described following head trauma (associated with base of skull or sinus fractures), epidurual injections or complicating neuro, spinal, craniofacial or sinus surgery. Unfortunately the signs and symptoms of TP are non-specific and the diagnosis must be made by prompt recognition of the classic imaging signs of TP, allowing lifesaving emergency decompression. We present a trauma patient demonstrating the “Mount Fuji” sign on an unenhanced CT brain, which is reportedly specific for TP.
- 1 May 2016
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 2 (2) , 20150127
Open AccessTension pneumocephalus: the neurosurgical emergency equivalent of tension pneumothorax
Tension pneumocephalus (TP) is the intra-cranial equivalent of tension pneumothorax. It is rare a life-threatening neurosurgical emergency, which has been described following head trauma (associated with base of skull or sinus fractures), epidurual injections or complicating neuro, spinal, craniofacial or sinus surgery. Unfortunately the signs and symptoms of TP are non-specific and the diagnosis must be made by prompt recognition of the classic imaging signs of TP, allowing lifesaving emergency decompression. We present a trauma patient demonstrating the “Mount Fuji” sign on an unenhanced CT brain, which is reportedly specific for TP.
- 1 February 2016
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 27 (2) , 194-199
Transcatheter Embolization of Type IA Endoleak after Nellix Endovascular Aortic Aneurysm Sealing with N-Butyl Cyanoacrylate: Technique in Three Patients
- 1 February 2016
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 27 (2) , 194-199
Transcatheter Embolization of Type IA Endoleak after Nellix Endovascular Aortic Aneurysm Sealing with N-Butyl Cyanoacrylate: Technique in Three Patients